Craig-Hallum analyst Anthony Stoss started Akoustis (AKTS) with a Buy rating and $8 price target. The analyst notes that the company sits in a "unique position" with BAW filters designed with a proprietary single crystal structure. Its filters offer superior performance at higher frequencies than the two dominant players - Broadcom (AVGO) and Qorvo (QRVO) - as they can handle higher power, have better acoustic performance, transfer heat out much faster, and are 23-times smaller. Stoss believes these characteristics will allow Akoustis to penetrate three enormous markets in a meaningful way.

05/13/19

CHLM

05/13/19NO CHANGETarget $12CHLMBuy

Akoustis price target raised to $12 from $10 at Craig-Hallum

Craig-Hallum analyst Anthony Stoss raised his price target for Akoustis Technologies to $12 from $10 after the company announced that it received its first purchase order from a multi-billion dollar tier-1 wireless telecommunications company to develop 5 GHz BAW filters for mobile handsets. Akoustis is also now in talks with multiple tier-1 handset manufacturers for their filter solutions, Stoss tells investors in a research note. He believes the company is seeing heavy customer interest and reiterates a Buy rating on the shares.

05/13/19

OPCO

05/13/19NO CHANGETarget $10OPCOOutperform

Akoustis top line to continue accelerating, says Oppenheimer

Oppenheimer analyst Rick Schafer kept his Outperform rating and $10 price target on Akoustis after its Q3 results, saying that earnings were short of consensus, but some of the company's military sales had been pushed out to Q4. The analyst notes that investor focus falls on the company's handset market, which is Akoustis' "top volume opportunity," and expects its top line to accelerate as Akoustis translates order wins into revenues.

Canaccord analyst Chip Moore raised his price target on Ameresco to $19.50 from $16.50 following solid Q4 results. The analyst cited its fully contracted back log which provides good visibility, the continued acceleration of its asset portfolio, and what he sees as an attractive risk/reward. Moore reiterated his Buy rating on Ameresco shares.

12/19/18

RILY

12/19/18INITIATIONTarget $17.5RILYBuy

Ameresco initiated with a Buy at B. Riley FBR

B. Riley FBR analyst Carter Driscoll started Ameresco with a Buy rating and $17.50 price target. The company's recurring revenue and backlog make it a "defensive play on efficiency," Driscoll tells investors in a research note.

03/04/19

ROTH

03/04/19UPGRADETarget $19ROTHBuy

Ameresco upgraded to Buy from Neutral at Roth Capital

Roth Capital analyst Craig Irwin upgraded Ameresco to Buy from Neutral as he expects the company to report "strong" Q4 results, supported by rising ESPC project activity and continued strengthening of the EBITDA contribution from the Canton-GNG plant. Looking forward, the Phoenix-GNG plant should drive a $15M step up in 2019 EBITDA, in addition to the tail from the 2018 Canton ramp, pointing to good potential for execution well above consensus, he contends. Irwin also raised his price target on the shares to $19 from $16.

Roth Capital analyst Darren Aftahi says weakness from Apple's (AAPL) negative pre-announcement, citing primarily emerging market weakness and fewer iPhone upgrades, could spill over into Digital Turbine (APPS). The analyst would be a buyer on any material weakness given Digital Turbine has no handset exposure to China and its exposure is to the Android based platform, where handsets tend to skew lower on ASP, in general. Apple weakness could create buying opportunity, he contends. Aftahi reiterates a Buy rating and $3 price target on Digital Turbine's shares.

B. Riley FBR analyst Sameet Sinha views the selloff yesterday in shares of Digital Turbine (APPS) on Google's (GOOG, GOOGL) potential changes to Chrome as a buying opportunity. The analyst believes the changes should have a minimal impact on Digital Turbine and keeps a Buy rating on the shares with a $4 price target. The stock closed yesterday down 14% to $3.09.

03/27/19

ROTH

03/27/19NO CHANGETarget $4.25ROTHBuy

Digital Turbine selloff creates buying opportunity, says Roth Capital

Roth Capital analyst Darren Aftahi believes Digital Turbine's (APPS) shares were weak on chatter about changes Google (GOOG; GOOGL) could make to its Chrome browser and third-party ad-targeting restrictions. The analyst argues that the company was lumped into this basket, when in fact about 85% of its revenue still comes from dynamic pre-load with the remaining 15% from new services, which to his knowledge have little if most likely any exposure to Google. Aftahi would be "accumulating on unnecessary weakness." He reiterates a Buy rating and a $4.25 price target on Digital Turbine's shares.

EGANeGain

$8.13

-0.065 (-0.79%)

09/07/18

ROTH

09/07/18NO CHANGETarget $16ROTHBuy

eGain FY19 guidance looks conservative, says Roth Capital

Roth Capital analyst Richard Baldry noted that eGain's initial FY19 guidance was moderately below his forecast, but he also believes that it appears conservative as he sees the company being positioned to at least grow SaaS revenues on par with FY18, and perhaps better. He reiterates a Buy rating and $16 price target on eGain shares.

As previously reported, Craig-Hallum analyst Jeff Van Rhee downgraded eGain to Hold from Buy following quarterly results as he awaits a more attractive risk/reward profile. The analyst has increased concerns around churn and the attractiveness of the platform to new customers. He also lowered his price target on the shares to $10 from $12.

07/18/18

NEED

07/18/18INITIATIONTarget $16NEEDBuy

eGain initiated with a Buy at Needham

Needham analyst Ryan MacDonald imitated eGain with a Buy and $16 price target saying it is a leading provider of cloud-based customer engagement software and expects a re-acceleration of revenue growth and margin expansion in FY19 and FY20, which justifies a premium valuation.

OSSOne Stop Systems

$2.12

-0.06 (-2.75%)

04/04/19

NBLE

04/04/19INITIATIONTarget $4NBLEOutperform

One Stop Systems initiated with an Outperform at Noble Capital

Noble Capital analyst Joe Gomes initiated One Stop Systems with an Outperform and $4 price target Gomes said One Stop Systems is a leader in the High Performance Computing space with particular emphasis on the "AI on the Fly" and the migration to PCI Express Gen 4 spaces through the design and manufacture of custom servers, compute accelerators, solid-state storage arrays, and system expansion systems. The analyst sees multiple avenues of growth from a ramp-up of existing OEM and military design wins, winning new OEM and military design awards, and an ongoing acquisition program to expand the depth of the company's offerings.

OPRXOptimizeRx

$13.39

-0.14 (-1.03%)

01/03/19

WBLR

01/03/19INITIATIONWBLROutperform

OptimizeRx well positioned for 'industry mega trends,' says William Blair

William Blair analyst Ryan Daniels initiated coverage of OptimizeRx with an Outperform rating. The analyst laid out six primary reasons for why he views OptimizeRx shares as an attractive small-cap healthcare technology holding. OptimizeRx's solutions address a critical, but largely unmet need for both pharmaceutical companies and physicians, Daniels tells investors in a research note. Further, he believes it is well positioned to benefit from "several industry mega trends" that will drive organic growth.

01/03/19

01/03/19INITIATION

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cision (CISN) initiated with a Neutral at Goldman Sachs. 2. Cheniere Energy (LNG) initiated with a Buy at UBS. 3. OptimizeRx (OPRX) initiated with an Outperform at William Blair. 4. Comerica (CMA) initiated with a Buy at Argus. 5. Kirkland Lake Gold (KL) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

01/03/19

WBLR

01/03/19INITIATIONWBLROutperform

OptimizeRx initiated with an Outperform at William Blair

William Blair analyst Ryan Daniels started OptimizeRx with an Outperform rating.

11/06/18

ROTH

11/06/18NO CHANGETarget $30ROTHBuy

OptimizeRx price target raised to $30 from $25 at Roth Capital

Roth Capital analyst Richard Baldry lowered his price target for OptimizeRx to $30 from $25 on "impressive" Q3 results, with 75% organic growth supporting record revenues, a second quarter of GAAP profitability, growing pro forma EPS and 28% adjusted operating margins. The analyst reiterates a Buy rating on the shares.

MVISMicroVision

$0.87

-0.0255 (-2.85%)

12/19/18

CHLM

12/19/18INITIATIONTarget $1.75CHLMBuy

MicroVision initiated with a Buy at Craig-Hallum

Craig-Hallum analyst Mike Malouf started MicroVision with a Buy rating and $1.75 price target. The analyst's optimistic case scenario assumes the smart Smart Speaker market grows to 100M units over the next few years, with 6.5M units incorporating the company's display-only capability and 3M integrating its interactive display functionality. Including other verticals, Malouf believes the company could generate $300M in revenue and over $50M in EBITDA, which at 8 times results in a $3.50 stock, or a 500% return.

MTBCMTBC, Inc

$4.99

-0.1 (-1.96%)

01/23/19

HCWC

01/23/19NO CHANGETarget $6HCWCBuy

Medical Transcription Billing called a 'top choice' for 2019 at H.C. Wainwright

H.C. Wainwright analyst Kevin Dede says Medical Transcription Billing is "woefully under-appreciated and worthy of an aggressive call to attention for small cap investors despite the currently volatile market environment." He thinks the stock has the potential to be one of the best performers in his coverage universe this year and reiterates a Buy rating on the name with a $6 price target.

Benchmark analyst Mark Schappel attributed the fact that Mitek Systems shares advanced more than 6.5% yesterday and are up 9% during the past week to takeover speculation, stating that some investors may believe that an announcement around a potential deal could be near. He raised his price target on Mitek shares to $15 from $12 to account for multiple expansion in the broader software sector and keeps a Buy rating on the stock.

03/29/19

BNCH

03/29/19NO CHANGETarget $15BNCHBuy

Mitek Systems takeover price of $20 'not out of the question,' says Benchmark

Benchmark analyst Mark Schappel said his $15 price target on Mitek Systems "may be one of the more aggressive ones on the Street," but based on recent transactions in the space he believes it is on the conservative side. In a takeover scenario, Schappel thinks Mitek could fetch up to $18.50 per share and does not think $20 per share "is out of the question," he tells investors. In a previous note to investors, Schappel attributed recent strength in Mitek Systems shares to takeover speculation, the Fly notes. The analyst keeps a Buy rating and $15 price target on Mitek shares.

Benchmark analyst Mark Schappel said Mitek Systems reported good Q2 results, but this is being overshadowed by the announcement that the company rejected all outstanding buyout offers and concluded its strategic review process. While not surprised to see the stock trade down in afterhours following the news, he thinks "a few more quarters of consistent execution" can get the stock trading up to the 5x revenue range and Schappel keeps a Buy rating on Mitek, which he believes should start trading on fundamentals. He trimmed his price target on Mitek to $14 from $15.

12/27/18

BNCH

12/27/18NO CHANGETarget $12BNCHBuy

Benchmark says Mitek could be worth $12-$13 per share in 'normal' environment

After Mitek Systems disclosed that it has received expressions of interest from multiple parties and that activist hedge fund Elliott Management has withdrawn its nomination of a dissident slate of directors since the company is evaluating its options, including a possible sale or merger, Benchmark analyst Mark W. Schappel said his "long held" view has been that Mitek could be worth $12-$13 per share "in a more normal operating environment." The analyst, who said that the news and Elliott's $11.50 outstanding bid "suggests that our inclinations are largely correct," keeps a Buy rating on Mitek shares with a $12 price target.

LMNRLimoneira

$21.99

-1 (-4.35%)

01/08/19

SPHN

01/08/19INITIATIONTarget $24SPHNOverweight

Limoneira initiated with an Overweight at Stephens

Stephens analyst Ben Bienvenu initiated coverage of Limoneira with an Overweight rating and $24 price target, stating that it has a unique position and portfolio of assets along with a "compelling" long-term growth story. He sees Limoneira's earnings approaching an inflection point that he expects to begin in FY19, Bienvenu added.

09/11/18

LSCM

09/11/18NO CHANGETarget $31LSCMBuy

Limoneira shares will likely sell off today, says Lake Street

Lake Street analyst Chris Krueger expects shares of Limoneira to sell off today following last night's earnings shortfall on weather. The stock had risen 65% since February and was pricing in expectations of a Q3 beat and guidance increase, neither of which happened, Krueger tells investors in a post-earnings research note. While sales beat estimates, poor weather hurt margins and caused an earnings miss, the analyst explains. However, he remains confident Limoneira will continue to grow its core agribusiness and generate additional cash flow from its real estate and water rights. Krueger raised his price target for the shares to $31 from $30 and keeps Buy rating on the name.

09/11/18

BUCK

09/11/18NO CHANGETarget $32BUCKBuy

Limoneira positioned for another year of growth, says Buckingham

Buckingham analyst Eric Larson raised his price target for Limoneira to $32 from $30, while reiterating a Buy rating on the shares. The analyst believes Limoneira is still positioned for another year of growth in FY18 behind a new efficient lemon packing plant, increased lemon volumes, additional lemon acreage, and a solid return to profitability in oranges. Further, additional runway for growth in FY19 is now being supported by two accretive acquisitions, he adds.

05/14/19

SPHN

05/14/19DOWNGRADETarget $18SPHNEqual Weight

Limoneira downgraded to Equal Weight from Overweight at Stephens

Stephens analyst Ben Bienvenu downgraded Limoneira to Equal Weight from Overweight and lowered his price target for the shares to $18 from $25. While the company lowered its full year guidance, second half of 2019 expectations remain too aggressive to totally eliminate the risk of another guidance reduction later in the year, Bienvenu tells investors in a research note. The analyst expects Limoneira shares to trade off today given the magnitude of the Q2 miss and lack of visibility into the remainder of fiscal 2019.

EVEREverQuote

$11.22

0.5 (4.66%)

04/04/19

JMPS

04/04/19NO CHANGETarget $12JMPSOutperform

EverQuote price target lowered to $12 from $18 at JMP Securities

JMP Securities analyst Ronald Josey said he believes that EverQuote is making progress in growing consumer demand, adding more carriers, improving carrier integrations and launching newer verticals and that progress in its core demand channels seen in Q4 has continued thus far in Q1. However, given increasing investments in marketing and advertising in 2019 and beyond, he lowered his price target on EverQuote shares to $12 from $18. Josey keeps an Outperform rating on the stock.

05/07/19

JPMS

05/07/19NO CHANGETarget $14JPMSOverweight

EverQuote price target raised to $14 from $12 at JPMorgan

JPMorgan analyst Doug Anmuth raised his price target for EverQuote to $14 from $12 saying the company's Q1 results were "solidly above expectations across the board." This was a "clean" beat and raise quarter and the newly announced health insurance vertical is a positive surprise, Anmuth tells investors in a research note. He keeps an Overweight rating on EverQuote shares.

02/26/19

02/26/19UPGRADE

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

02/26/19

BOFA

02/26/19UPGRADETarget $10.5BOFABuy

EverQuote upgraded to Buy following Q4 beat at BofA/Merrill

As previously reported, BofA/Merrill upgraded EverQuote to Buy from Neutral with a new $10.50 price target following the Q4 beat. Analyst Nat Schindler said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive.

RBBNRibbon Communications

$4.75

-0.08 (-1.66%)

08/01/18

COWN

08/01/18UPGRADECOWNMarket Perform

Ribbon Communications upgraded to Market Perform from Underperform at Cowen

INVEIdentiv

$5.10

(0.00%)

05/01/19

05/01/19INITIATION

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Buy at Tigress Financial. 2. Waste Management (WM) and Republic Services (RSG) were initiated with a Sector Perform at RBC Capital. 3. Identiv (INVE) initiated with an Outperform at Oppenheimer. 4. The Stars Group (TSG) initiated with an Equal Weight at Morgan Stanley. 5. Avid Technology (AVID) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

04/15/19

LSCM

04/15/19NO CHANGETarget $9LSCMBuy

Identiv pullback brings buying opportunity, says Lake Street

Lake Street analyst Jaeson Schmidt views the recent pullback in shares of Identiv as a buying opportunity. After meeting with management and seeing some product demos at the International Security Conference & Exposition West last week, the analyst feels confident Identiv remains on track to see sustained revenue growth and achieve profitability this year. While the stock is down 21% since reporting Q4 results in early March, Schmidt does not think there has been any deterioration in the company's fundamentals. He sees an attractive entry point at current levels and reiterates a Buy rating on Identiv with a $9 price target.

04/30/19

OPCO

04/30/19INITIATIONTarget $7OPCOOutperform

Identiv initiated with an Outperform at Oppenheimer

Oppenheimer analyst Andrew Uerkwitz initiated Identiv with an Outperform rating and a price target of $7, calling the company a "microcap gem" in a growing and evolving access control market. The analyst is positive on the company's 3-year run of optimizing the business around its "core competency" with new acquired technology to accelerate its transition to a full suite offering, and expects Identiv to gain market share while growing faster than its peers.

04/30/19

OPCO

04/30/19INITIATIONOPCOOutperform

Identiv initiated with an Outperform at Oppenheimer

NPNeenah Paper

$60.15

-2.17 (-3.48%)

02/13/19

DADA

02/13/19NO CHANGETarget $77DADANeutral

Neenah Paper price target lowered to $77 from $88 at DA Davidson

DA Davidson analyst Steven Chercover lowered his price target on Neenah Paper to $77 and kept his Neutral rating, saying its "soft" Q4 results have completed a "challenging" 2018 as input cost inflation cut into the company's operating profits. The analyst notes that while the management is confident in generating positive pricing momentum in 2019, he expects that it will "take some time before EBITDA margins bounce back to the mid-teen levels posted in recent years."

RESNResonant

$3.05

-0.11 (-3.48%)

06/21/18

LOOP

06/21/18INITIATIONTarget $11LOOPBuy

Resonant initiated with a Buy at Loop Capital

Loop Capital analyst Cody Acree initiated Resonant with a Buy rating and a price target of $11. The analyst cites the company's Infinite Synthesized Network platform technology - "a software-based, high-precision modeling approach that is able to produce real-world testable results in a completed design" which allows Resonant to eliminate design flaws in the software before wafer production begins. Acree believes that this approach will be much more "attractive to the market than the traditional method of running multiple physical iterations through a wafer fab".

11/14/18

LOOP

11/14/18NO CHANGETarget $7LOOPBuy

Resonant price target lowered to $7 from $11 at Loop Capital

Loop Capital analyst Cody Acree lowered his price target on Resonant to $7 to reflect the "valuation contractions across the chip industry" along with his revisions of its royalty revenue timeline driven by its customers' pushout of their expected handset launch into the first half of 2019. The analyst also keeps his Buy rating on the shares, stating that the steady progress made by Resonant in "growing its funnel of engagements" should yield a "material revenue ramp in 2019". Acree further contends that the company is "well positioned to become a material supplier of advanced filter designs targeting the China market".

H.C. Wainwright analyst Kevin Dede said that the exit of Mike Seifert from Resonant only weeks after he joined as the company's second-ever CFO on September 2 "may raise both red flags and hackles on the back of the neck," but he clearly does not agree with anyone suggesting that a worse case scenario is behind this morning's news. He attributes the company's hiring and subsequent loss of Siefert as being due to "poor due diligence and a seemingly rash decision," and notes that Jeff Killian, the company's original CFO now turned consultant, has returned to his old post until a committed replacement can be found. Dede, who would use the "knee jerk reaction" in the stock as an opportunity to enlarge an investment position, keeps a Buy rating and $8 price target on Resonant shares, which are down 5% to $4.15 in early trading.

08/10/18

LOOP

08/10/18NO CHANGETarget $11LOOPBuy

Loop Capital encouranged by Resonant development process

Loop Capital analyst Cody Acree kept his Buy rating and $11 price target on Resonant after its Q2 results despite the company's reduction of FY18 revenue growth target from mid-single-digit millions to low-single-digit millions. The analyst notes that the outlook change is mainly due to end-customer timing rather than the company's development delays, adding that he remains encouraged by Resonant's pace of progress.

CPSTCapstone Turbine

$0.76

-0.0384 (-4.82%)

08/01/18

08/01/18INITIATION

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Capstone Turbine (CPST) initiated with a Buy at Maxim. 2. Lilis Energy (LLEX) initiated with a Buy at Stifel. 3. SS&C (SSNC) assumed with an Overweight at JPMorgan. 4. Magnolia Oil & Gas (MGY) initiated with an Outperform at Imperial Capital. 5. Fate Therapeutics (FATE) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

08/01/18

MAXM

08/01/18INITIATIONTarget $2.5MAXMBuy

Capstone Turbine initiated with a Buy at Maxim

Maxim analyst James Jang initiated Capstone Turbine with a Buy rating and a price target of $2.50. The analyst notes that the company's market divsersification should support its revenue expansion trend as it builds sales momentum. Jang further states that the shale oil industry is a key driver for Capstone's growth as its microturbines allow for reduced operating costs for its customers.

H.C. Wainwright analyst Amit Dayal believes the 50% pullback in shares of Capstone Turbine since mid-July overlooks the company's revenue and margin drivers. There are "several catalysts in the story that support a healthy outlook for the company," Dayal tells investors in a research note. These include the recently launched Distributor Support System with $1.1M in funding, demand for lower cost remanufactured systems, expansion in Russia, Middle East, Africa and South America, Dayal writes. He maintains a Buy rating on Capstone Turbine with a $2.00 price target.

02/08/19

ROTH

02/08/19DOWNGRADETarget $0.9ROTHNeutral

Capstone Turbine downgraded to Neutral from Buy at Roth Capital

Roth Capital analyst Craig Irwin downgraded Capstone Turbine to Neutral from Buy after the company's Q3 revenue missed expectations, noting that its microturbine gross margins were negative again. The analyst, who now thinks material progress on microturbine gross margins "is looking increasingly unlikely," expects product margins excluding parts and spares to be a "source of continued disappointment," he tells investors in a post-earnings research note. Irwin lowered his price target on Capstone shares to 90c from $1.25.

OPYOppenheimer Holdings

$25.39

-0.92 (-3.50%)

SSTIShotSpotter

$43.58

-0.93 (-2.09%)

03/05/19

03/05/19NO CHANGE

ShotSpotter files to sell an aggregate of 386k shares of common stock

JMP Securities is acting as the sole underwriter for the offering.

05/10/19

WBLR

05/10/19NO CHANGEWBLROutperform

ShotSpotter selloff brings good entry point, says William Blair

William Blair analyst Matthew Pfau believes today's post-earnings selloff in shares of ShotSpotter provides a good entry point. The analyst admits, however, that ShotSpotter shares will likely be in the penalty box for several quarters as management regains investor confidence. With that said, Pfau does not think the recent customer loss highlighted by management is indicative of a broader trend. Further, ShotSpotter is selling to cities and municipalities, and the red tape in getting deals approved can be substantial and create the potential for delays, adds the analyst. Pfau keeps an Outperform rating on ShotSpotter shares.

05/10/19

LSCM

05/10/19NO CHANGETarget $50LSCMBuy

ShotSpotter earnings selloff a buying opportunity, says Lake Street

Lake Street analyst Jaeson Schmidt recommends using the post-earnings selloff in shares of ShotSpotter as a buying opportunity. The greater than 20% selloff is less reflective of any significant change to ShotSpotter's growth opportunities and more illustrative of a stock that was up 42% quarter-to-date and "priced for perfection," Schmidt tells investors in a research note. He continues to believe ShotSpotter is positioned to drive meaningful top line growth and improving profitability going forward. The analyst lowered his price target for the shares to $50 from $55 and keeps a Buy rating on the name.

05/10/19

DOTC

05/10/19DOWNGRADEDOTCNeutral

ShotSpotter downgraded to Neutral from Buy at Dougherty

Dougherty analyst Jeremy Hamblin downgraded ShotSpotter to Neutral from Buy without a price target following the company's Q1 results.

According to a regulatory filing, Ryan Graves informed Uber Technologies of his intention to resign as a member of the company's board of directors, effective as of May 27, 2019, including any committees of the board of directors on which he serves. Graves' resignation was not the result of any disagreement between Graves and the company, its management, board of directors or any committee thereof, or with respect to any matter relating to the company's operations, policies or practices, according to the filing.

U.S. Energy announced that on May 21, Nasdaq notified the company that as a result of not having received its Quarterly Report on Form 10-Q for the period ended March 31. 2019, and because the company is delinquent in filing its Form 10-K for the year ended December 31, 2018, the company does not comply with the requirements of Nasdaq Listing Rule 5250(c)(1) for continued listing on the Exchange. This notification has no effect on the listing of the company's common stock at this time. However, pursuant to the notice, the company was required to submit a plan by May 23, 2019 to comply with the Exchange's requirements for continued listing.

Apple is being sued by customers alleging that the U.S. tech giant is unlawfully disclosing and selling information about users' iTunes purchases as well as their personal data, Bloomberg's Robert Burnson reports. The customers claim that such alleged practices are contrary to Apple's promise in advertising that "What happens on your iPhone stays on your iPhone," Burnson notes. Reference Link

SuperCom received a notification from Nasdaq for not having timely filed its Annual Report on Form 20-F for the year ended December 31, 2018, as previously disclosed by the company on May 16, 2019. The company does not comply with the Nasdaq Listing Rule 5250(c)(1). This notice from Nasdaq has no effect currently on the listing of the company's common stock on the Nasdaq Capital Market.

U.S. Energy announced that Nasdaq notified the company that as a result of not having received the company's quarterly report on Form 10-Q for the period ended March 31 and because the company is delinquent in filing its Form 10-K for the year ended December 31, 2018, the company does not comply with the requirements of Nasdaq Listing Rule 5250 for continued listing on the exchange. This notification has no effect on the listing of the company's common stock at this time. However, pursuant to the notice, the company was required to submit a plan by May 23 to comply with the exchange's requirements for continued listing. The company has submitted the plan to the exchange. If the exchange accepts the company's Plan, the exchange may grant an exception of up to 180 calendar days from the Form 10-K's due date, or until October 14 to regain compliance. The company continues to work toward the filing of the Form 10-Q and the Form 10-K with the SEC as soon as practicable.

Qiagen (QGEN) announced the launch of its therascreen PIK3CA RGQ PCR Kit after it received U.S. regulatory approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY, a newly approved therapy developed and marketed by Novartis (NVS). The therascreen PIK3CA Kit is the first companion diagnostic assay to obtain premarket approval from the FDA for use in any cancer indication for detection of activating mutations in the PIK3CA gene. It is also the first FDA approved assay for guiding treatment decisions in breast cancer using plasma specimens as a liquid biopsy.

Brazil's ANAC said it has suspended all flights and operations of Avianca Brasil in the South American nation as a precuartionary measure, Reuters reports. The move follows Avianca's filing for bankruptcy in late 2018, the report says. "All the flights are suspended until the company proves it has the capacity to maintain operations safely," ANAC said. Reference Link

Apple has bought Tueo Health, a start-up that was making a system to help parents monitor asthma symptoms in sleeping kids, CNBC's Christina Farr and Steve Kovach report, citing a person familiar with the deal. It is not clear how much the U.S. tech giant paid for the start-up, the authors note. Reference Link

A review of Boeing's grounded 737 MAX aircraft has expanded to include emergency procedures used by pilots on earlier models of the plane, further delaying its return to service, the Wall Street Journal's Andy Pasztor reports, citing U.S. government officials. The FAA hasn't questioned the safety of older aircraft currently in service, but the broadened review will play a major role in adding months to the time expected to get the grounded fleet of 737 MAX jets back in the skies, Pasztor notes. As part of the FAA's safety analysis of a proposed software fix for the fleet, the agency is also weighing changes to how pilots of the entire 737 family are trained to respond when the flight-control computer or other systems suddenly push the jet's nose down, the author says. Reference Link

The CBOE Volatility Index (VIX), the SPX option derived measure of implied volatility, fell 1.07 today to close at 15.85, while the underlying SPX index gained 3.82 to close at $2826.06, a 0.14% increase. 274,267 VIX option contracts traded, 38.73% of the typical daily volume for the product. Calls made up 74.0% of the volume.

Volume was average for this time of day. Breadth was mixed with issues and volume bullish while new highs to new lows were bearish (negative divergence). Advancing Issues: 2009 / Declining Issues: 1048 -- for a ratio of 1.9 to 1. Advancing Volume: 915,942,000 / Declining Volume: 681,710,000 -- for a ratio of 1.3 to 1. New 52-Week Highs: 57 / New 52-Week Lows: 114.

Volume was below average for this time of day. Breadth was bullish across the board. Advancing Issues: 1963 / Declining Issues: 956 -- for a ratio of 2.1 to 1. Advancing Volume: 1,549,354,000 / Declining Volume: 986,891,000 -- for a ratio of 1.6 to 1. New 52-Week Highs: 138 / New 52-Week Lows: 89.

Regional Health Properties, Inc. announcement concerning the company's noncompliance with the continued listing standards of NYSE American LLC. On May 21, 2019, the company received an official notice of noncompliance from the Exchange stating that the company is not in compliance with the Exchange's continued listing standards under the timely filing criteria outlined in Section 1007 of the Exchange's company Guide because the company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2019, which was due to be filed with the Securities and Exchange Commission no later than May 20, 2019. For the reasons previously disclosed in its Form 12b-25 filed with the Securities and Exchange Commission on May 16, 2019, the company has not timely filed the Delayed Form 10-Q because additional time is needed to finalize the Delayed Form 10-Q and furnish the XBRL Interactive Data File exhibits required by Item 601b101 of Regulation S-K. The company is actively working to complete the Delayed Form 10-Q and intends to file the Delayed Form 10-Q under the Securities Exchange Act of 1934, as amended, within the next thirty days. As a result of the foregoing, the company has become subject to the procedures and requirements of Section 1007 of the Company Guide. During the six-month period from the date of the Filing Delinquency, the Exchange will monitor the company and the status of the Delayed Form 10-Q and any subsequent reports until the Filing Delinquency is cured. If the company fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in its sole discretion, allow the company's securities to be traded for up to an additional six-month period, depending on the company's specific circumstances. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set forth in Section 1010 of the Company Guide.